| Literature DB >> 19284557 |
Ann-Charlotte Elkan1, Niclas Håkansson, Johan Frostegård, Tommy Cederholm, Ingiäld Hafström.
Abstract
INTRODUCTION: Patients with rheumatoid arthritis (RA) have an increased risk for cardiovascular disease (CVD) independent of traditional risk factors. The aim of this study was to analyze the associations between diet, body composition, lipids and atheroprotective natural antibodies against phosphorylcholine (anti-PC) in patients with RA.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19284557 PMCID: PMC2688183 DOI: 10.1186/ar2643
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Patient characteristics
| Age, years | 60.8 (57.3 to 64.4) | 63.4 (59.8 to 66.9) |
| Disease duration, yearsa | 6.0 (2.0 to 15.0) | 5.0 (3.0 to 9.0) |
| Rheumatoid factor positive, N (%) | 51 (84) | 14 (74) |
| Erosive disease, N (%) | 47 (77) | 14 (74) |
| ESR, mm/ha | 16.0 (9.0 to 29.0) | 12.0 (9.0 to 15.0) |
| C-reactive protein, mg/la | 2.0 (1.0 to 8.0) | 3.0 (1.0 to 9.0) |
| DAS28 | 3.3 (3.0 to 3.6) | 2.6 (2.1 to 3.0) |
| HAQ score (0 to 3) | 0.7 (0.5 to 0.8) | 0.5 (0.2 to 0.7) |
| Patients on DMARDs, N (%) | 59 (97) | 19 (100) |
| Patients on glucocorticoids, N (%) | 17 (28) | 3 (16) |
| Glucocorticoids, dose, mg | 4.3 (3.4 to 5.3) | 4.2 (0.6 to 7.8) |
| Hypertension, N (%) | 33 (54) | 13 (68) |
| MetS, N (%) | 12 (20) | 12 (63) |
Data is presented as mean (95% confidence intervals) for normally distributed variables and as median (interquartile range) for non-parametric variables.
aMedian.
DAS28, 28-joint Disease Activity Score (where a value of >5.1 is regarded as high disease activity, <3.2 is regarded as low activity and <2.6 is regarded as remission); ESR, erythrocyte sedimentation rate; DMARD, disease-modifying antirheumatic drug (for example, methotrexate, sulfasalazine, hydroxychloroquine, cyclosporine, natriumaurotiomalat and azathioprine); HAQ, Health Assessment Questionnaire; MetS, metabolic syndrome.
Energy intake according to food frequency questionnaire (FFQ) in rheumatoid arthritis (RA) patients and Swedish recommendations for low active individuals
| Energy, kcal | 1,668 (1,537 to 1,799) | 2,200 | 2,402 (2,123 to 2,680) | 2,700 |
| Carbohydrate, g | 195 (178 to 212) | 293 | 268 (238 to 298) | 369 |
| Carbohydrate, E% | 48 | 55 | 45 | 55 |
| Protein, g | 73.0 (66.7 to 79.3) | 86 | 103 (88.4 to 118) | 107 |
| Protein, g/kg | 1.13 (1.01 to 1.23) | 1.18 (1.0 to 1.36) | ||
| Protein, E% | 18 | 16 | 17 | 16 |
| Total fat, g | 61.1 (55.8 to 66.4) | 69 | 88.6 (75.1 to 102.1) | 87 |
| Total fat, E% | 33 | 28 | 33 | 28 |
| SFA, g | 26.4 (23.7 to 29.0) | 20 | 39.1 (31.9 to 46.2) | 30 |
| SFA, E% | 14 | 10 | 15 | 10 |
| MUFA, g | 21.0 (19.2 to 22.8) | 30 | 30.9 (26.5 to 35.2) | 40 |
| MUFA, E% | 11 | 11 | 12 | 11 |
| PUFA, g | 8.9 (7.9 to 9.8) | 15 to 30 | 11.8 (9.8 to 13.8) | 15 to 30 |
| PUFA, E% | 4.8 | 5 | 4.4 | 5 |
| Omega 3 FA, g | 1.9 (1.8–2.1) | ≥ 3.0 | 1.7 (1.6–1.8) | ≥ 3.0 |
| Omega 3 FA, E% | 1.0 | 1.3 | 0.6 | 1.3 |
| Omega 6 FA, g | 6.9 (6.2 to 7.7) | 10.8 | 11.0 (10.4 to 11.5) | 10.8 |
| Omega 6 FA, E% | 3.7 | 3.6 | 4.1 | 3.6 |
E%, energy percentage; FA, fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid.
Spearman correlation coefficients between relative (% of total fat) fatty acid (FA) diet intake calculated from food frequency questionnaire (FFQ) and FA in adipose tissue
| 14:0, AT | 0.27** | ||||||||
| 16:0, AT | -0.12 | ||||||||
| 18:1 n9, AT | 0.21 | ||||||||
| 18:2 n6, AT | 0.50* | ||||||||
| 18:3 n3, AT | 0.48* | ||||||||
| 20:4 n6, AT | 0.64* | ||||||||
| 20:5 n3, AT | 0.71* | ||||||||
| 22:5 n3, AT | 0.78* | ||||||||
| 22:6 n3, AT | 0.82* |
*P < 0.001, **P < 0.05
AT = adipose tissue.
Fatty acids in adipose tissue and serum levels of lipids and anti-PC IgM in women with rheumatoid arthritis (RA), separated for diet
| Normal diet (n = 46) | Mediterranean-like diet (n = 12) | Mediterranean-like and vegetarian diets (n = 15) | |||
| Adipose tissue: | |||||
| SFA | 29.2 (28.4 to 29.9) | 29.1 (27.5 to 30.7) | 0.60 | 28.8 (27.5 to 30.1) | 0.90 |
| 14:0 | 3.3 (3.1 to 3.5) | 3.4 (3.1 to 3.8) | 0.60 | 3.5 (3.2 to 3.8) | 0.43 |
| 16:0 | 21.7 (21.2 to 22.2) | 21.7 (20.4 to 23.1) | 0.92 | 21.4 (20.2 to 22.5) | 0.55 |
| MUFA | 57.4 (56.7 to 58.1) | 56.1 (54.6 to 57.6) | 0.06 | 55.8 (54.4 to 57.2) | |
| 16:1 n7 | 6.5 (6.0 to 6.9) | 6.0 (5.3 to 6.6) | 0.30 | 5.8 (5.2 to 6.4) | 0.13 |
| 18:1 n9 | 51.4 (50.9 to 52.0) | 50.2 (48.9 to 51.2) | 50.0 (49.0 to 51.0) | ||
| Omega 3 | 1.8 (1.7 to 1.9) | 2.1 (1.7 to 2.6) | 2.2 (1.8 to 2.6) | ||
| 18:3 n3 | 1.1 (1.0 to 1.2) | 1.1 (0.93 to 1.2) | 0.72 | 1.1 (1.0 to 1.3) | 0.22 |
| 20:5 n3 | 0.14 (0.12 to 0.16) | 0.19 (0.12 to 0.25)* | 0.08 | 0.15 (0.11 to 0.25)* | 0.16 |
| 22:5 n3 | 0.33 (0.29 to 0.37) | 0.40 (0.31 to 0.50) | 0.06 | 0.39 (0.29 to 0.48) | 0.11 |
| 22:6 n3 | 0.32 (0.28 to 0.36) | 0.47 (0.25 to 0.59)* | 0.07 | 0.47 (0.20 to 0.60)* | 0.13 |
| Omega 6 | 11.0 (10.6 to 11.3) | 12.0 (10.7 to 13.2) | 0.06 | 12.6 (11.2 to 14.1) | |
| 18:2 n6 | 10.1 (9.7 to 10.5) | 11.2 (9.8 to 12.5) | 0.06 | 11.9 (10.4 to 13.4) | |
| 20:4 n6 | 0.40 (0.36 to 0.44) | 0.39 (0.31 to 0.46) | 0.81 | 0.32 (0.26 to 0.45)* | 0.35 |
| Serum lipids: | |||||
| Cholesterol, mmol/l | 5.3 (5.0 to 5.6) | 5.1 (4.7 to 5.6) | 0.60 | 5.1 (4.8 to 5.5) | 0.57 |
| HDL, mmol/l | 1.9 (1.7 to 2.0) | 1.9 (1.4 to 2.4) | 0.97 | 1.9 (1.5 to 2.3) | 0.86 |
| LDL, mmol/l | 2.9 (2.7 to 3.2) | 2.8 (2.3 to 3.2) | 0.58 | 2.8 (2.3 to 3.2) | 0.52 |
| OxLDL, U/l | 62.1 (55.7 to 68.4) | 59.4 (50.0 to 68.9) | 0.67 | 58.8 (51.2 to 66.3) | 0.57 |
| Triacylglycerol, mmol/l | 0.98 (0.88 to 1.1) | 1.0 (0.82 to 1.2) | 0.63 | 1.0 (0.81 to 1.1) | 0.95 |
| anti-PC IgM, U/mla | 43.5 (30.3 to 65.5) | 198.2 (171.6 to 209.2) | 188.2 (63.3 to 208.1) |
Values are means (95% confidence interval) and amedians (interquartile range). The fatty acids in adipose tissue are expressed as a percentage of total fat. Significant results are in bold.
Anti-PC IgM, antibodies against phosphorylcholine IgM; FA, fatty acid; HDL< high-density lipoprotein; LDL, low-density lipoprotein; MUFA, monounsaturated fatty acid; oxLDL, oxidized low-density lipoprotein; PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid.
Anthropometry and body composition measurement in rheumatoid arthritis (RA) patients
| Women (n = 61) | Men (n = 19) | |
| Weight change since disease onset, kg | 2.3 (-0.8 to 5.9) | 4.4 (-2.2 to 8.0) |
| BMI, kg/m2 | 25.0 (23.6 to 26.3) | 27.0 (25.7 to 29.1) |
| Waist circumference, cm | 85 (81 to 89) | 105 (100 to 110) |
| Central obesity (WC >80 cm in women, >94 cm in men), N (%) | 35 (57) | 17 (89) |
| FM, total, kg | 25.8 (22.8 to 28.7) | 27.9 (23.4 to 32.5) |
| FM, total, % | 37.8 (35.7 to 39.9) | 31.7 (28.1 to 35.2) |
| FMI, kg/m2 | 8.8 (6.5 to 11.4)a | 8.6 (7.2 to 9.9) |
| FFM, total, kg | 42.0 (40.6 to 43.5) | 61.2 (58.6 to 63.8) |
| FFMI, kg/m2 | 15.5 (15.1 to 15.9) | 18.9 (18.2 to 19.6) |
Data is presented as mean (95% confidence interval) for normally distributed variables and as median (interquartile range) for non-parametric variables.
aMedian
BMI, body mass index; FFM, fat free mass; FFMI, fat free mass index; FM, fat mass; FMI, fat mass index; WC, waist circumference.